Background: Traditional pharmacovigilance (PV) has historically relied on reactive functional changes, such as a decrease in Left Ventricular Ejection Fraction (LVEF). However, the emergence of targeted therapies demands a shift toward proactive, molecular-level surveillance [1].

Objective: This article explores modern strategies for cardiac signal detection in early- phase trials, emphasizing the integration of high-sensitivity biomarkers and advanced imaging [2].

Conclusion: Modernizing PV through "Precision MPharmacovigilance (PV), Drug safety surveillance, Adverse drug reactions (ADR), Signal detection, Risk management.onitoring" enhances participant safety and prevents premature attrition of drug candidates [3].